Table 1.
Selection Regimen | Cell Line | Drug | ABC Transporter Overexpressed |
---|---|---|---|
Multi-step | KB-3-1 | Colchicine | ABCB1 (13) |
Doxorubicin | ABCB1 (13) | ||
Vinblastine | ABCB1 (13) | ||
Multi-step | OVCAR-8 | Doxorubicin | ABCB1 (14; 15) |
Multi-step | MCF-7 | Doxorubicin | ABCB1 (17) |
Multi-step | MES-SA | Doxorubicin | ABCB1 (19) |
Multi-step | MCF-7 | Docetaxel | ABCB1 (20) |
Multi-step | MDA-MB-231 | Docetaxel | ABCB1 (20) |
Multi-step | MCF-7 | Doxorubicin | ABCB1 and ABCG2 (21; 22) |
Multi-step | MCF-7 | Paclitaxel | ABCB1 and ABCG2 (21; 22) |
Multi-step | NCI-H69 | Doxorubicin | ABCC1 (23) |
Multi-step | COR-L23 | Doxorubicin | ABCC1 (24; 25) |
Multi-step | MOR | Doxorubicin | ABCC1 (24; 25) |
Multi-step | GLC4 | Doxorubicin | ABCC1 (26) |
Multi-step | MCF-7 | Etoposide | ABCC1 (27) |
Multi-step | NCI-H69 | Etoposide | ABCB1 and ABCC1 (28) |
Multi-step | MCF-7 | Flavopiridol | ABCG2 (29) |
Multi-step | MCF-7 | Doxorubicin and verapamil |
ABCG2 (30) |
Multi-step | MCF-7 | Mitoxantrone | ABCG2 (31) |
Multi-step | S1 | Mitoxantrone | ABCG2 (32) |
Multi-step | IGROV-1 | Topotecan | ABCG2 (33) |
Multi-step | IGROV-1 | Mitoxantrone | ABCG2 (33) |
Multi-step | SF295 | Mitoxantrone | ABCG2 (34) |
Multi-step | GLC4 | Mitoxantrone | ABCA2 (35) |
Single-step | MCF-7 | Doxorubicin | ABCC4 and ABCG2* (10) |
Single-step | MCF-7 | Etoposide | ABCG2 (10) |
Single-step | IGROV-1 | Doxorubicin | ABCG2 (10) |
Single-step | S1 | Doxorubicin | ABCG2 (10) |
Single-step | MES-SA | Doxorubicin | ABCB1 (57) |
Single-step | MES-SA | Paclitaxel | ABCB1 (59) |
Single-step | NCI-H82 | Epirubicin | ABCC1 (62) |
Single-step | GLC4 | Doxorubicin | ABCC1 (63) |
In all cases the overexpression of an ABC transporter was demonstrated at the functional level and the references are given in the parenthesis.
ABCG2 is the ABC transporter responsible for MDR and ABCC4 does not confer resistance to doxorubicin.